Physician profile
David J Lafferty
NPI 1063952463
$9,258.77
in general payments reported to CMS, 2019-2025
18 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 90% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $21.40 · 2021: $481 · 2022: $188 · 2023: $1,800 · 2024: $4,414 · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150 · Travel and Lodging: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.43 |
| Travel and Lodging | $3,218.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $2,629.34 | 2019-2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Med-El Corporation | $1,447.86 | 2024-2025 | Mi1250 Synchrony 2 Flexsoft, Bci 602 Kit, Adhear Professional Kit |
| Acclarent, INC | $1,360.51 | 2023 | Trudi Nav Cable |
| Genzyme Corporation | $616.66 | 2021-2025 | |
| Integra Lifesciences Corporation | $597.63 | 2021-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Medtronic, INC. | $425.91 | 2024-2025 | Pteye Parathyroid Detection System, Propel |
| Regeneron Healthcare Solutions, INC. | $399.38 | 2021-2025 | Dupixent |
| Smith+Nephew, INC. | $357.31 | 2022-2025 | Halo, Tula, Coblation |
| Optinose US, INC. | $328.32 | 2021-2024 | |
| Abbvie INC. | $316.06 | 2023-2024 | |
| Aerin Medical INC. | $195.73 | 2023-2025 | |
| Intersect Ent, INC. | $171.05 | 2019-2020 | |
| Stryker Corporation | $161.71 | 2025 | Audion Et Dilation System |
| Glaxosmithkline, LLC. | $123.67 | 2024-2025 | Nucala |
| Neurent Medical Limited | $59.99 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.40 | 2025 | Voquezna |
| Amgen INC. | $20.18 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $20.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.